Boris Azaïs is Director Public Policy Europe at MSD, a global research-based pharmaceutical company also known as Merck & Co., Inc. in the US and Canada. He is also member of the board of EuropaBio and Chair of EFPIA’s Health Systems Working Group.
In his role, Boris engages with European institutions and governments to promote a policy framework that drives pharmaceutical companies to engage in high-risk and high-cost research and development efforts and develop ground-breaking treatments and vaccines for the benefit of European patients. His focus is at the nexus of science, healthcare, and industrial policy, which together are at the origin of about all medicines and vaccines ever developed.
Boris is the author of research papers, blog posts, and policy material, including MSD’s Policy Passport on Pharmaceutical Innovation, which can be found at https://efpia.eu/news-events/
For his full biography and a sample of his production and interventions, please go to https://www.linkedin.com/in/